HealthEquity, Inc. (NASDAQ:HQY) Shares Sold by Bamco Inc. NY

Bamco Inc. NY lessened its stake in HealthEquity, Inc. (NASDAQ:HQY) by 6.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shares of the company’s stock after selling 50,000 shares during the period. Bamco Inc. NY’s holdings in HealthEquity were worth $61,388,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in shares of HealthEquity in the 2nd quarter valued at $35,000. Paladin Wealth LLC acquired a new position in shares of HealthEquity in the third quarter worth about $39,000. GAMMA Investing LLC raised its position in shares of HealthEquity by 114.8% in the second quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after acquiring an additional 318 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity during the 2nd quarter worth about $73,000. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of HealthEquity during the 3rd quarter valued at about $112,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insiders Place Their Bets

In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. The trade was a 13.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the sale, the director now directly owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. This trade represents a 21.54 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,536 shares of company stock valued at $884,517. Insiders own 2.20% of the company’s stock.

HealthEquity Stock Performance

HQY opened at $101.54 on Monday. HealthEquity, Inc. has a twelve month low of $62.10 and a twelve month high of $105.82. The firm has a market capitalization of $8.87 billion, a PE ratio of 84.62, a PEG ratio of 1.59 and a beta of 0.52. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The firm’s 50-day moving average price is $90.16 and its 200 day moving average price is $82.81.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The business had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million. As a group, sell-side analysts expect that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HQY has been the subject of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft upped their target price on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. BTIG Research lifted their price target on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Bank of America upped their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Barrington Research reiterated an “outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.